Percy Griffin holds a Ph.D. in Molecular Cell Biology from Washington University in St. Louis and an M.Sc. in Pharmacology from the University of Minnesota. Dr. Griffin focuses his practice on intellectual property law matters including support of validity, infringement, and patentability analysis in the biotechnology area. With a background in pharmacology, he is experienced in the drug discovery process. Other areas of expertise include:

• • Neurodegenerative diseases
  • Protein degradation
  • Neuroimmunology
  • Cell Biology
  • Oncology
  • Molecular Biology

Prior to joining MBHB Dr. Griffin served as Director of Scientific Engagement at the Alzheimer’s Association. In this role, he worked stakeholders from academia, industry, and regulators to advance research and treatment for Alzheimer’s and other dementias. He served as a spokesperson for the organization in that role. He held other roles in life science consulting and drug discovery.

Dr. Griffin’s graduate research focused on the intersection between circadian rhythms, neuroinflammation and Alzheimer’s diseases. At Washington University in St. Louis, Dr. Griffin was awarded the National Science Foundation Graduate Research Fellowship (NSF-GRFP) and the Neuroscience Scholars Program Fellowship (NSP) from the Society for Neuroscience (SfN). He completed the Science Communication Credential and served as a scientific editor and illustrator for InPrint, a publication editing service at Washington University. He also served as a consultant for the Biotechnology and Life Sciences Advisory Group.

Hammers DB, Eloyan A, Taurone A, Thangarajah M, Beckett L, Gao S, Kirby K, Aisen P, Dage JL, Foroud T, Griffin P, Grinberg LT, Jack CR Jr, Kramer J, Koeppe R, Kukull WA, Mundada NS, La Joie R, Soleimani-Meigooni DN, Iaccarino L, Murray ME, Nudelman K, Polsinelli AJ, Rumbaugh M, Toga A, Touroutoglou A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez MF, Womack K, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG; LEADS Consortium, Profiling baseline performance on the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) cohort near the midpoint of data collection (2023), Alzheimers Dement. doi: 10.1002/alz.13160

Polsinelli AJ, Wonderlin RJ, Hammers DB, Garcia AP, Eloyan A, Taurone A, Thangarajah M, Beckett L, Gao S, Wang S, Kirby K, Logan PE, Aisen P, Dage JL, Foroud T, Griffin P, Iaccarino L, Kramer JH, Koeppe R, Kukull WA, La Joie R, Mundada NS, Murray ME, Nudelman K, Soleimani-Meigooni DN, Rumbaugh M, Toga AW, Touroutoglou A, Vemuri P, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez MF, Womack K, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG; LEADS Consortium, Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) cohort (2023), Alzheimers Dement doi: 10.1002/alz.13344

Eloyan A, Thangarajah M, An N, Borowski BJ, Reddy AL, Aisen P, Dage JL, Foroud T, Ghetti B, Griffin P, Hammers D, Iaccarino L, Jack CR Jr, Kirby K, Kramer J, Koeppe R, Kukull WA, La Joie R, Mundada NS, Murray ME, Nudelman K, Rumbaugh M, Soleimani-Meigooni DN, Toga A, Touroutoglou A, Atri A, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu J, Mendez MF, Musiek E, Onyike CU, Rogalski E, Salloway S, Sha S, Turner RS, Wingo TS, Wolk DA, Womack K, Beckett L, Gao S, Carrillo MC, Rabinovici G, Apostolova LG, Dickerson B, Vemuri P; and the LEADS Consortium, White matter hyperintensities are higher among early-onset Alzheimer’s disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer’s Disease Study (LEADS) (2023), Alzheimers Dement. doi: 10.1002/alz.13402

Dage JL, Eloyan A, Thangarajah M, Hammers DB, Fagan AM, Gray JD, Schindler SE, Snoddy C, Nudelman KNH, Faber KM, Foroud T, Aisen P, Griffin P, Grinberg LT, Iaccarino L, Kirby K, Kramer J, Koeppe R, Kukull WA, La Joie R, Mundada NS, Murray ME, Rumbaugh M, Soleimani-Meigooni DN, Toga AW, Touroutoglou A, Vemuri P, Atri A, Beckett LA, Day GS, Graff-Radford NR, Duara R, Honig LS, Jones DT, Masdeu JC, Mendez MF, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Womack KB, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG; LEADS Consortium, Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer’s Disease Study (2023), Alzheimer’s Dement. doi: 10.1002/alz.13399

Wiese LAK, Gibson A, Guest MA, Nelson AR, Weaver R, Gupta A, Carmichael O, Lewis JP, Lindauer A, Loi S, Peterson R, Radford K, Rhodus EK, Wong CG, Zuelsdorff M, Saidi LG, Valdivieso-Mora E, Franzen S, Pope CN, Killian TS, Shrestha HL, Heyn PC, Ng TKS, Prusaczyk B, John S, Kulshreshtha A, Sheffler JL, Besser L, Daniel V, Tolea MI, Miller J, Musyimi C, Corkey J, Yank V, Williams CL, Rahemi Z, Park J, Magzamen S, Newton RL Jr, Harrington C, Flatt JD, Arora S, Walter S, Griffin P, Babulal GM, Global rural health disparities in Alzheimer’s disease and related dementias: State of the science (2023), Alzheimers Dement. doi: 10.1002/alz.13104

Griffin P, Apostolova L, Dickerson BC, Rabinovici G, Salloway S, Brandt K, Masdeu J, Hammers D, Raghuram S, Hall S, Carrillo MC. Developments in understanding early onset Alzheimer’s disease (2023), Alzheimers Dement. doi: 10.1002/alz.13353

Griffin P, Sheehan P, Dimitry J, Guo C, Kanan M, Lee J, Zhang J, Musiek ES. REV-ERBa mediates complement expression and diurnal regulation of microglial synaptic phagocytosis (2020), eLife;9:e58765. doi: 10.7554/eLife.58765.

Lee J, Kim D, Griffin P, Sheehan P, Kim DH, Musiek ES. Inhibition of REV-ERBs Stimulates Microglial Amyloid-Beta and Reduces Plaque-Deposition in the 5XFAD Mouse Model of Alzheimer’s Disease (2019), Aging Cell, e13078. doi: 10.1111/acel.13078.

Griffin P, Dimitry J, Musiek ES. Rev-Erbs and Glia: Implications for Neurodegenerative Diseases (2019) J Exp Neurosci. doi: 10.1177/1179069519853233.

Griffin P*, Dimitry J*, Sheehan P, Lananna BV, Robinette ML, Cedeño MR, Nadarajah C, Guo C, Ezerskiy LA, Colonna M, Zhang J, Bauer AQ, Burris T, Musiek ES. The circadian clock protein Rev-erba regulates neuroinflammation. (2019) Proc Natl Acad Sci USA 116(11):5102-5107

Lananna BV, Nadarajah CJ, Izumo M, Cedeño MR, Xiong DD, Dimitry J, Tso CF, McKee CA, Griffin P, Sheehan PW, Haspel JA, Barres BA, Liddelow SA, Takahashi JS, Karatsoreos IN, Musiek ES. Cell-autonomous regulation of astrocyte activation by the circadian clock protein BMAL1 (2018) Cell Rep 25(1): 1-9.E5.

Griffin P, Sexton A, MacNeill L, Iizuka Y, Lee MK, Bazarro M, (2015) “Method for measuring the activity of deubiquitinating enzymes in cell lines and tissue samples.” J Vis Exp. (99): e52784.

Brisbois RG, Bergan AM, Ellison AJ, Griffin P, Hackbarth KC, Larson SR, (2013) “Thermal, Non-Catalyzed Huisgen Cycloaddition for the Preparation of 4,5-Bis(trimethylsilyl)-1H-1,2,3-triazoles.” Tet Lett. 54(12): 272-276.